Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is Myelodysplasia a Consequence of Normal Aging?
Heibl S, Stauder R, Pfeilstöcker M. Heibl S, et al. Curr Oncol Rep. 2021 Nov 4;23(12):142. doi: 10.1007/s11912-021-01136-5. Curr Oncol Rep. 2021. PMID: 34735656 Free PMC article. Review.
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
Geissler K, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Borjan B, Jilch R, Geissler C, Hoermann G, Esterbauer H, Schwarzinger I, Nösslinger T, Pfeilstöcker M, Tüchler H, Reisner R, Sliwa T, Keil F, Bettelheim P, Machherndl-Spandl S, Doleschal B, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Petzer A, Kusec R, Ulsperger E, Schneeweiss B, Berger J, Öhler L, Germing U, Sperr WR, Knöbl P, Jäger U, Valent P. Geissler K, et al. Among authors: heibl s. Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418. doi: 10.1007/s00508-019-1526-1. Epub 2019 Jul 18. Wien Klin Wochenschr. 2019. PMID: 31321531 Free PMC article.
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
Geissler K, Jäger E, Barna A, Gurbisz M, Graf T, Graf E, Nösslinger T, Pfeilstöcker M, Tüchler H, Sliwa T, Keil F, Geissler C, Heibl S, Thaler J, Machherndl-Spandl S, Zach O, Weltermann A, Bettelheim P, Stauder R, Zebisch A, Sill H, Schwarzinger I, Schneeweiss B, Öhler L, Ulsperger E, Kusec R, Germing U, Sperr WR, Knöbl P, Jäger U, Hörmann G, Valent P. Geissler K, et al. Among authors: heibl s. Int J Mol Sci. 2020 Apr 24;21(8):3025. doi: 10.3390/ijms21083025. Int J Mol Sci. 2020. PMID: 32344757 Free PMC article.
Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype.
Heibl S, Gisslinger B, Jäger E, Barna A, Gurbisz M, Stegemann M, Bettelheim P, Machherndl-Spandl S, Pfeilstöcker M, Nösslinger T, Uyanik G, Hoermann G, Stauder R, Thaler J, Kusec R, Valent P, Gisslinger H, Geissler K. Heibl S, et al. Cancers (Basel). 2020 Jul 14;12(7):1891. doi: 10.3390/cancers12071891. Cancers (Basel). 2020. PMID: 32674283 Free PMC article.
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Füreder W, Sperr WR, Heibl S, Zebisch A, Pfeilstöcker M, Stefanzl G, Jäger E, Greiner G, Schwarzinger I, Kundi M, Keil F, Hoermann G, Bettelheim P, Valent P. Füreder W, et al. Among authors: heibl s. Ann Hematol. 2020 Oct;99(10):2303-2313. doi: 10.1007/s00277-020-04214-z. Epub 2020 Aug 27. Ann Hematol. 2020. PMID: 32856141
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.
Machherndl-Spandl S, Jäger E, Barna A, Gurbisz M, Marschon R, Graf T, Graf E, Geissler C, Hoermann G, Nösslinger T, Pfeilstöcker M, Bettelheim P, Zach O, Weltermann A, Heibl S, Thaler J, Zebisch A, Sill H, Stauder R, Webersinke G, Kusec R, Ulsperger E, Schneeweiss B, Öhler L, Germing U, Valent P, Tüchler H, Geissler K. Machherndl-Spandl S, et al. Among authors: heibl s. Eur J Haematol. 2021 Aug;107(2):265-274. doi: 10.1111/ejh.13647. Epub 2021 Jun 1. Eur J Haematol. 2021. PMID: 33998054 Free PMC article.
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Leisch M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Hartmann B, Petzer A, Schreder M, Kiesl D, Vallet S, Egle A, Melchardt T, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Drost M, Greil R, Pleyer L. Leisch M, et al. Among authors: heibl s. Cancers (Basel). 2022 May 17;14(10):2459. doi: 10.3390/cancers14102459. Cancers (Basel). 2022. PMID: 35626063 Free PMC article.
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, Stute N, Föhrenbach Quiroz KT, Leisch M, Egle A, Scagnetti L, Wolf D, Beswick R, Drost M, Larcher-Senn J, Grochtdreis T, Vaisband M, Hasenauer J, Zaborsky N, Greil R, Stauder R. Pleyer L, et al. Among authors: heibl s. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388. Cancers (Basel). 2023. PMID: 36900181 Free PMC article.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Pleyer L, Vaisband M, Drost M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Petzer A, Schreder M, Schmitt CA, Vallet S, Melchardt T, Zebisch A, Pichler P, Zaborsky N, Machherndl-Spandl S, Wolf D, Keil F, Hasenauer J, Larcher-Senn J, Greil R. Pleyer L, et al. Among authors: heibl s. Am J Hematol. 2023 Nov;98(11):1685-1698. doi: 10.1002/ajh.27046. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548390
Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review.
Piringer G, Decker J, Trommet V, Kühr T, Heibl S, Dörfler K, Thaler J. Piringer G, et al. Among authors: heibl s. Front Oncol. 2023 May 5;13:1166545. doi: 10.3389/fonc.2023.1166545. eCollection 2023. Front Oncol. 2023. PMID: 37213293 Free PMC article.
31 results